Drugs in MeSH Category Steroid Synthesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208453-001	Oct 31, 2018	AB	RX	No	No
Glenmark Speclt	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	209227-001	Oct 16, 2019	AB	RX	No	No
Amneal Pharms	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208327-002	Dec 23, 2020	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Steroid Synthesis Inhibitors

Last updated: April 25, 2026

What is the current commercial footprint of “steroid synthesis inhibitors”?

Steroid synthesis inhibitors are endocrine drugs that block enzymes in the androgen and/or corticosteroid biosynthesis pathways. The market is concentrated in a small number of well-established actives used in prostate cancer (androgen biosynthesis/androgen production suppression) and congenital adrenal hyperplasia (CAH) (adrenal steroid deficiency management). Pricing power and duration of demand depend on:

• Indication depth (oncology vs chronic endocrine replacement)
• Line-of-therapy positioning (pre-chemo vs post-chemo in mCRPC; standard-of-care in CAH)
• Formulation and adherence (oral availability and dosing frequency)
• Regulatory exclusivity stacking (primary patents plus method-of-use and formulation patents, with pediatric exclusivity when applicable)

Prime commercial actives (typical category coverage)

Common actives that map to steroid biosynthesis inhibition in clinical practice and that drive the category’s patent “center of gravity” include:

• Abiraterone (CYP17A1 inhibitor; mCRPC, mHSPC, and off-label settings)
• Ketoconazole (broad steroidogenesis inhibitor; historically used in Cushing’s and other settings)
• Orteronel (CYP17A1 inhibitor; development outcomes historically unfavorable vs abiraterone in key settings)
• Osilodrostat (CYP11B1 inhibitor; CAH and related disorders)
• VORINostat is unrelated (included here only to clarify scope): steroid synthesis inhibitors are steroidogenic enzyme blockers, not histone deacetylase inhibitors.

Market dynamic headline: the category’s economic engine is dominated by abiraterone’s long-duration commercial presence, with newer entries in CAH attempting to establish durable brand share through chronic use economics and disease-specific regulatory approvals.

---

How do market dynamics differ between oncology steroid synthesis inhibition and CAH steroidogenesis inhibition?

Oncology (prostate cancer): high value per patient, competitive sequencing

• Demand durability: sustained by inclusion across multiple stages and combinations.
• Switching friction: high because treatments are tightly linked to regimen outcomes and established patient tolerance patterns.
• Patent term pressure: oncology creates dense “evergreening” because additional indications, combination regimens, and dosing optimizations can extend value.

Competitive implication: generic entry is economically constrained until broad patent barriers clear, and even then, uptake depends on physician trust and payer restrictions.

CAH and related adrenal disorders: chronic therapy with dosing- and safety-driven adoption

• Demand durability: chronic and steady, with long patient lifetimes.
• Safety and monitoring: central to payer and physician decisions because adrenal steroid balance requires lab monitoring.
• Titration strategy: dose-adjustment guidance and monitoring protocols can carry patent protection.

Competitive implication: smaller molecules with narrow enzyme target specificity (for example, CYP11B1) can defend position through clinical protocol patents even when chemical composition becomes vulnerable.

---

What is the patent landscape pattern in this MeSH class?

The patent landscape for steroid synthesis inhibitors typically clusters into four layers:

1. Composition of matter (CoM) for the active
2. Process claims for manufacturing intermediates or final API
3. Formulation claims (crystal form, salt, particle size, release profile, or food-effect mitigation)
4. Method-of-use claims:
   • Indication expansion (new disease, new stage)
   • Patient subtype (biomarker-defined)
   • Combination therapy (with ADT, AR antagonists, chemo, steroids)
   • Dosing and titration strategy

Patent “attack surface” for generic and biosimilar-style challengers

• CoM expiry is necessary but often insufficient; use and formulation patents can extend market protection.
• Manufacturing process patents can block cheaper supply if process-specific barriers exist.
• Regulatory exclusivity can add a non-patent wall (notably for first-in-class approvals).

---

Where does patent density sit by active ingredient?

The category’s patent density is highest for the long-commercialized first wave (notably abiraterone) and then migrates to method-of-use and formulation around newer entries (for example, CAH agents).

Patent landscape map (by archetype, not company-by-company)

Patent layer	Typical claim target	Practical effect on market	Where it concentrates
CoM	compound structure and analogs	sets first expiry trigger	early filings and continuation families
Process	synthetic route, intermediates	can block generic manufacturing	manufacturing and scale-up patents
Formulation	particle size, crystallinity, food effects	preserves brand dosing advantages	oral products and bioavailability improvements
Method of use	indication, combinations, dosing regimens	delays generic switching by extending labeled benefit	oncology sequencing + CAH monitoring protocols

---

What do enforcement and litigation signals typically look like in this class?

Steroid synthesis inhibitors tend to be litigated when generic applicants target:

• mCRPC and earlier lines where outcome data define value,
• label expansions tied to clinical trial programs,
• combination regimens that are part of standard-of-care pathways,
• formulation substitutes that aim to avoid brand dosing restrictions.

Common litigation structure in the space:

• Generic applicants file for approval with a Paragraph IV-type challenge when CoM patents are still in force.
• The innovator asserts a portfolio spanning CoM, formulation, and method-of-use.
• Courts often narrow to claim sets that map directly to the asserted product’s infringement theory, usually focusing on use regimens and formulation parameters.

---

How should investors and R&D teams model competitive timelines?

Model three date buckets per active:

1. Core CoM expiry (first barrier)
2. Secondary patent expiry (formulation + use)
3. Regulatory and lifecycle offsets (label expansions and exclusivity end)

In steroid synthesis inhibition, the second bucket often dominates because even after CoM expiry, physicians and payers can remain locked into branded regimens if competitors cannot legally market the same use.

---

What is the practical market dynamic for abiraterone-style CYP17A1 inhibition?

CYP17A1 inhibitors are the flagship economics in this class because they address the androgen biosynthesis pathway that drives prostate cancer survival.

Commercial drivers

• Positioning across disease stages (late and earlier)
• Established clinical management protocols
• Combination therapy playbooks that reduce willingness to switch during patent runway

Patent leverage mechanisms

• Multiple continuation filings around analogs and salts
• Method-of-use expansions around combination and sequencing
• Formulation and dosing claims that reduce generic substitutability

---

What is the practical market dynamic for CAH-targeting CYP11B1 inhibition?

CAH therapy is a chronic disease economics play where competitive advantage comes from:

• stable steroid control with manageable monitoring burden,
• predictable titration under clinical protocols,
• reduced adverse event risk in routine long-term use.

Patent leverage mechanisms

• dosing/titration method claims
• monitoring and therapeutic adjustment protocols
• patient subsets and treatment targets

---

What is the near-term diligence checklist for this MeSH class?

A complete diligence pass for any compound in this class should map the entire portfolio into infringement-relevant categories:

• Is there a formulation patent that covers the brand’s bioavailability edge (food effect, particle size, crystallinity)?
• Are method-of-use claims tied to combination regimens used in current guideline pathways?
• Are process patents present that could constrain generic manufacturing?
• Are there continuation family members that keep at least one claim family alive well beyond the core CoM expiry?

This directly predicts whether a “CoM-expired” product still behaves like a de facto brand.

---

Key Takeaways

• The MeSH class “Steroid Synthesis Inhibitors” is economically driven by a small set of entrenched actives, with CYP17A1 inhibitors (oncology) and CYP11B1 inhibition (CAH) defining the two dominant demand curves.
• Patent protection typically extends beyond composition through formulation and method-of-use layers, delaying switching even when primary CoM expires.
• Competitive timelines should be modeled with three buckets: CoM expiry, secondary patent expiry, and regulatory/label offsets, because the second bucket often governs practical market access.
• For diligence and valuation, the critical questions are not only “when does the CoM expire” but “can competitors legally market the same regimen and dosage profile that drives real-world uptake.”

---

FAQs

1) Which patent layers most often block generics in steroid synthesis inhibition?
Formulation and method-of-use claims that tie to labeled regimens and dosing protocols.

2) Why do oncology steroid synthesis inhibitors stay branded longer than expected?
Because combination therapy and sequencing generate enforceable method-of-use claims that preserve switching friction.

3) What makes CAH steroidogenesis inhibition different from oncology?
Adoption depends on chronic dosing stability and safety monitoring protocols, which are easier to patent via therapeutic adjustment and monitoring claims.

4) What is the fastest way for a competitor to erode market share in this class?
Launching a legally compliant product that matches not just the active but the regimen and formulation parameters that clinicians use.

5) What should be the first task in portfolio due diligence for this MeSH class?
Build a claim map that links portfolio members to likely infringement theories: compound, formulation, manufacturing, and method-of-use.

---

References

No cited sources were used.